Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cue Biopharma, Inc. | d592193dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 25, 2018
Cue Biopharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
001-38327 |
47-3324577 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 675 W. Kendall St., Cambridge, MA |
02142 | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code): (617) 949-2680
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Information |
On May 25, 2018 Cue Biopharma, Inc. (the “Company”) announced a change to the location of its annual meeting of stockholders scheduled for Tuesday, June 12, 2018 (the “2018 Annual Meeting”). The meeting date, time and record date remain unchanged.
The new location for the 2018 Annual Meeting will be:
The Warwick Melrose Hotel
Oak Lawn Terrace Conference Room
3015 Oak Lawn Ave
Dallas, Texas 75219
The time of the 2018 Annual Meeting will be 9:00 a.m., local time.
A copy of the notice to stockholders regarding this change in meeting location is furnished with this Form 8-K as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |
| 99.1 | Notice to Stockholders dated May 25, 2018. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cue Biopharma, Inc. | ||||||||
| Date: May 25, 2018 | By: | /s/ Daniel R. Passeri | ||||||
| Name: Title: |
Daniel R. Passeri Chief Executive Officer | |||||||